Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Council Resource
Issue Brief
Partner Resource
Policy Recommendation
Press Release

Biosimilars are a prescription for better health.

Biosimilars could lead to over $54 billion in savings over the next ten years, giving 1.2 million patients access to needed medicines.

Learn More

The Biosimilars Council - Dark Transparent Overlay

Working to ensure patient access to effective,
affordable biosimilars.

The Biosimilars Council is a division of the Association for Accessible Medicines.
We work to ensure a positive regulatory and policy environment for biosimilar medicines through educating the public and patients about the potential of biosimilar medicines.

Biosimilars: A needed alternative to costly care.

Utilization of innovative and very costly medicines is expected to grow exponentially in the coming years. With biosimilars, these advanced treatments are poised to become available at a lower cost to millions of patients in the United States. A positive regulatory environment can increase biosimilar adoption.


Browse our Media Selection

Read coverage of biosimilars in the news, hear more from experts on the potential of biosimilars, and learn about Biosimilars Council efforts to increase biosimilar access for patients.


Want to keep up-to-date?

Enter your email address below and receive the Biosimilars Bulletin – our monthly newsletter with the most recent information on biosimilars in the United States.

  • This field is for validation purposes and should be left unchanged.

Register for GRx+Biosims 2019 on November 4-6,2019 in Bethesda, Maryland to hear top officials and subject matter experts from the U.S. Food and Drug Administration (FDA), industry and academia, all designed to enhance understanding and knowledge sharing of the latest technical, policy, and regulatory information and expectations of the industry.


Featured Reports & Resources

These resources provide answers around what biosimilars are, why they are important, how they can improve patient access, and how they can save the United States billions of dollars.

The #insulin market in the U.S. is a prime example of the issues that #biosimilars struggle with broadly. Read more about the @US_FDA public meeting:

The 7.5 million patients who rely on #insulin don’t have access to #generic or #biosimilar insulin.

“...we know that patent thickets and overpatenting are a big barrier to adoption.” - @ChristinSimmon, @BiosimsCouncil Executive Director


The @US_FDA commissioner believes #biosimilars could be the answer to "intolerable" #insulin prices.

via @BioPharmaReport #accessiblemeds #diabetes #type1 #type2

Load More...